Sylvia M Brakenhoff
Overview
Explore the profile of Sylvia M Brakenhoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dongelmans E, Hirode G, Hansen B, Chen C, Su T, Seto W, et al.
J Hepatol
. 2025 Jan;
82(3):446-455.
PMID: 39773379
Background & Aims: Flares after nucleos(t)ide analogue (NA) cessation are common and potentially harmful. Predictors of flares are required for risk stratification and to guide off-treatment follow-up. Method: This multicenter...
2.
Dongelmans E, Feld J, Boonstra A, Brakenhoff S, Wong D, Yim C, et al.
Aliment Pharmacol Ther
. 2024 Dec;
61(3):570-578.
PMID: 39624922
Background: Severe flares (ALT ≥ 10×ULN) are a well-recognised adverse outcome after nucleos(t)ide analogue (NA) cessation and may lead to liver failure. Thus, identification of patients at risk for these...
3.
Brakenhoff S, Theijse T, van Wijngaarden P, Trautwein C, Brozat J, Tacke F, et al.
BMC Med Inform Decis Mak
. 2024 Aug;
24(1):227.
PMID: 39138441
Background And Aims: Systematic reviews and medical guidelines are widely used in clinical practice. However, these are often not up-to-date and focussed on the average patient. We therefore aimed to...
4.
Brakenhoff S, Chi H, Friederich P, Doukas M, Den Hoed C, Flink H, et al.
Case Rep Gastroenterol
. 2024 Apr;
18(1):252-259.
PMID: 38681803
Introduction: Emerging evidence suggests that long-term nucleos(t)ide analogue (NA) therapy can be ceased in a selective group of chronic hepatitis B (CHB). This is being gradually implemented in clinical practice....
5.
Hirode G, Hansen B, Chen C, Su T, Wong G, Seto W, et al.
Am J Gastroenterol
. 2024 Mar;
119(9):1849-1856.
PMID: 38483300
Introduction: Complete viral suppression with nucleos(t)ide analogs (NAs) has led to a profound reduction in hepatocellular carcinoma and mortality among patients with chronic hepatitis B. Finite therapy yields higher rates...
6.
Hirode G, Hansen B, Chen C, Su T, Wong G, Seto W, et al.
Am J Gastroenterol
. 2024 Mar;
119(10):2145.
PMID: 38457250
No abstract available.
7.
Brakenhoff S, Claassen M, Honkoop P, de Knegt R, van der Eijk A, Boonstra A, et al.
Clin Res Hepatol Gastroenterol
. 2023 Dec;
48(2):102257.
PMID: 38065523
Background & Aim(s): Current guidelines suggest that nucleos(t)ide analogues (NA) can be discontinued before HBsAg loss in a selected group of chronic hepatitis B (CHB) patients. We aimed to study...
8.
Sonneveld M, Chiu S, Park J, Brakenhoff S, Kaewdech A, Seto W, et al.
Gastroenterology
. 2023 Sep;
166(1):168-177.e8.
PMID: 37769952
Background & Aims: Patients who discontinue nucleo(s)tide analogue therapy are at risk of viral rebound and severe hepatitis flares, necessitating intensive off-treatment follow-up. Methods: We studied the association between hepatitis...
9.
van Dijk M, Boyd A, Brakenhoff S, Isfordink C, van Zoest R, Verhagen M, et al.
Liver Int
. 2023 Sep;
44(1):52-60.
PMID: 37718515
Background And Aims: The path to hepatitis C virus (HCV) elimination is complicated by individuals who become lost to follow-up (LTFU) during care, particularly before receiving effective HCV treatment. We...
10.
Sonneveld M, Chiu S, Park J, Brakenhoff S, Kaewdech A, Seto W, et al.
JHEP Rep
. 2023 Jul;
5(8):100790.
PMID: 37484211
Background & Aims: Pretreatment predictors of finite nucleo(s)tide analogue (NUC) therapy remain elusive. We studied the association between pretreatment HBV DNA levels and outcomes after therapy cessation. Methods: Patients with...